These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1653675)

  • 21. Monoclonal antibodies for clinical trials of Duchenne muscular dystrophy therapy.
    Le TL; Nguyen TM; Morris GE
    Neuromuscul Disord; 2014 Mar; 24(3):195-200. PubMed ID: 24361045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dystrobrevin deficiency at the sarcolemma of patients with muscular dystrophy.
    Metzinger L; Blake DJ; Squier MV; Anderson LV; Deconinck AE; Nawrotzki R; Hilton-Jones D; Davies KE
    Hum Mol Genet; 1997 Jul; 6(7):1185-91. PubMed ID: 9215691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterisation of dystrophin in fetuses at risk for Duchenne muscular dystrophy.
    Clerk A; Sewry CA; Dubowitz V; Strong PN
    J Neurol Sci; 1992 Aug; 111(1):82-91. PubMed ID: 1403002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterogeneity of dystrophin expression in patients with Duchenne and Becker muscular dystrophy.
    Nicholson LV; Johnson MA; Gardner-Medwin D; Bhattacharya S; Harris JB
    Acta Neuropathol; 1990; 80(3):239-50. PubMed ID: 2205076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dystrophin in skeletal muscle. II. Immunoreactivity in patients with Xp21 muscular dystrophy.
    Nicholson LV; Davison K; Johnson MA; Slater CR; Young C; Bhattacharya S; Gardner-Medwin D; Harris JB
    J Neurol Sci; 1989 Dec; 94(1-3):137-46. PubMed ID: 2693618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myoblast transfer in Duchenne muscular dystrophy.
    Karpati G; Ajdukovic D; Arnold D; Gledhill RB; Guttmann R; Holland P; Koch PA; Shoubridge E; Spence D; Vanasse M
    Ann Neurol; 1993 Jul; 34(1):8-17. PubMed ID: 8517684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dystrophin or a "related protein" in Duchenne muscular dystrophy?
    Nicholson LV; Johnson MA; Davison K; O'Donnell E; Falkous G; Barron M; Harris JB
    Acta Neurol Scand; 1992 Jul; 86(1):8-14. PubMed ID: 1519480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterisation of dystrophin in carriers of Duchenne muscular dystrophy.
    Clerk A; Rodillo E; Heckmatt JZ; Dubowitz V; Strong PN; Sewry CA
    J Neurol Sci; 1991 Apr; 102(2):197-205. PubMed ID: 2072119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The principles and practice of myoblast transfer.
    Karpati G
    Adv Exp Med Biol; 1990; 280():69-74. PubMed ID: 2248156
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunohistological evidence for second or somatic mutations as the underlying cause of dystrophin expression by isolated fibres in Xp21 muscular dystrophy of Duchenne-type severity.
    Wallgren-Pettersson C; Jasani B; Rosser LG; Lazarou LP; Nicholson LV; Clarke A
    J Neurol Sci; 1993 Aug; 118(1):56-63. PubMed ID: 8229051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monitoring duchenne muscular dystrophy gene therapy with epitope-specific monoclonal antibodies.
    Morris G; Man Nt; Sewry CA
    Methods Mol Biol; 2011; 709():39-61. PubMed ID: 21194020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical significance of dystrophin test for patients with various neuromuscular diseases--immunofluorescence and immunoblot analyses of dystrophin abnormalities].
    Ikeya K; Saito K; Yamauchi A; Kondo E; Komine S; Ikenaka H; Mishima M; Takahashi R; Harada T; Fukuyama Y
    No To Hattatsu; 1993 Jul; 25(4):328-34. PubMed ID: 8338694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunofluorescence dystrophin study in Duchenne dystrophy through the concomitant use of two antibodies directed against the carboxy-terminal and the amino-terminal region of the protein.
    Vainzof M; Zubrzycka-Gaarn EE; Rapaport D; Passos-Bueno MR; Pavanello RC; Pavanello-Filho I; Zatz M
    J Neurol Sci; 1991 Feb; 101(2):141-7. PubMed ID: 1709683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunological detection of the dystrophin molecule with antibody directed against the synthetic peptide.
    Ohta M; Ohta K; Hara H; Itoh N; Itagaki Y; Nishitani H; Hayashi K
    Biochem Int; 1991 Dec; 25(6):1087-93. PubMed ID: 1810253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune responses to dystropin: implications for gene therapy of Duchenne muscular dystrophy.
    Ferrer A; Wells KE; Wells DJ
    Gene Ther; 2000 Sep; 7(17):1439-46. PubMed ID: 11001363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The dilemma of manifesting carriers in the context of myoblast transplantation.
    Kunkel LM
    Adv Exp Med Biol; 1990; 280():285-6. PubMed ID: 2248149
    [No Abstract]   [Full Text] [Related]  

  • 37. Plausible structural/functional/behavioral/biochemical transformations following myoblast transfer therapy.
    Law PK; Goodwin TG; Li HJ; Chen M
    Adv Exp Med Biol; 1990; 280():241-9; discussion 249-50. PubMed ID: 2248145
    [No Abstract]   [Full Text] [Related]  

  • 38. Pilot study of myoblast transfer in the treatment of Becker muscular dystrophy.
    Neumeyer AM; Cros D; McKenna-Yasek D; Zawadzka A; Hoffman EP; Pegoraro E; Hunter RG; Munsat TL; Brown RH
    Neurology; 1998 Aug; 51(2):589-92. PubMed ID: 9710042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface.
    Bonilla E; Samitt CE; Miranda AF; Hays AP; Salviati G; DiMauro S; Kunkel LM; Hoffman EP; Rowland LP
    Cell; 1988 Aug; 54(4):447-52. PubMed ID: 3042151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preservation of the C-terminus of dystrophin molecule in the skeletal muscle from Becker muscular dystrophy.
    Arahata K; Beggs AH; Honda H; Ito S; Ishiura S; Tsukahara T; Ishiguro T; Eguchi C; Orimo S; Arikawa E
    J Neurol Sci; 1991 Feb; 101(2):148-56. PubMed ID: 2033400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.